Please ensure Javascript is enabled for purposes of website accessibility

Why Shares in Arrowhead Research Dropped Over 15% Today

By Todd Campbell - Jan 19, 2016 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were unimpressed by a decision by EU regulators to give ARC-AAT orphan drug status.

What: Despite reporting that EU regulators have designated its ARC-AAT as an orphan drug for a rare liver disease, shares in Arrowhead Research (ARWR 3.64%) slumped by 16.2% today.

So what: ARC-AAT is in clinical studies for use in treating patients with liver disease associated with alpha-1 antitrypsin deficiency (AATD).

In AATD patients, a genetic mutation causes the overproduction of malformed AAT, an inflammatory protein believed to cause of progressive liver disease. ARC-AAT's curbs the production of AAT, potentially halting disease progression and promoting tissue repair.

There are an estimated 100,000 people in the U.S. with this condition, and it affects less than five in 10,000 people in the EU.

Now what: The orphan designation in the EU reduces regulatory fees and provides for a longer 10-year period of exclusivity. ARC-AAT was similarly awarded orphan designation in the U.S. in 2015, so the EU's decision isn't unexpected.

Getting orphan designation, however, does not guarantee that ARC-AAT will prove to be efficacious and safe in its clinical trials, which remain in the early stages.

In addition to ARC-AAT, Arrowhead Research is developing other therapies that engineer RNA to alter protein expression, including ARC-520, a drug in development for hepatitis B. ARC-520 is in mid-stage results, and if successful, it could reshape hepatitis B treatment by providing an upstream therapy that delivers a functional cure.

Image source: Arrowhead Research.

Results from various ARC-520 monotherapy and combination therapy trials should be available this year and next year and phase 1 data for ARC-AAT is expected by the end of 2016. Overall, RNA therapies have struggled in the clinic, so investors might want to be patient and wait for results before considering this stock for portfolios. 

Todd Campbell owns shares of Arrowhead Research. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$47.29 (3.64%) $1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.